Search | Clinical Trials Finder

Conditions: HER2-positive Breast Cancer
Interventions: Atezolizumab, Paclitaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions: MT-6402; Drug
Lead sponsor: Molecular Templates, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more

Conditions: Malignant Melanoma
Interventions: Atezolizumab, Cobimetinib, Vemurafenib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography, Multigated Acquisition Scan, Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: INBRX-106, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 22 more

Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Interventions: Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 247
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more

Conditions: HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Interventions: Atezolizumab, Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more

Conditions: Neoplasms
Interventions: BI 765179, Ezabenlimab, Pembrolizumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 25
States / cities: Scottsdale, Arizona • Palo Alto, California • Santa Monica, California + 21 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions: Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review; Radiation · Biological · Drug + 2 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions: Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Other · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more

Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions: rezatapopt, pembrolizumab; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 25 more

Conditions: Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
Interventions: CX-2009, CX-072; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 27
States / cities: La Jolla, California • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: Pembrolizumab, Nivolumab; Drug
Lead sponsor: Hookipa Biotech GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Neoplasms, Head and Neck
Interventions: feladilimab, Pembrolizumab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Duarte, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 10 more

Conditions: Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions: Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab; Drug · Biological
Lead sponsor: Intima Bioscience, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Duarte, California • Minneapolis, Minnesota

Conditions: Lung Neoplasms, Non-Small-Cell Lung Carcinoma
Interventions: Pembrolizumab/Vibostolimab, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Boca Raton, Florida • Peoria, Illinois • Springfield, Missouri + 4 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab; Drug · Biological
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 15
States / cities: Fullerton, California • Orange City, Florida • Tampa, Florida + 12 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8
Interventions: Atezolizumab, Brachytherapy, Cisplatin, Radiation Therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 13 more

Conditions: Advanced PD-L1 Positive Malignancies
Interventions: 89Zr˗DFO˗REGN3504; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab, Leucovorin; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more

Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 55
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation
Interventions: Durvalumab, Carboplatin, Pemetrexed; Drug
Lead sponsor: Shirish M Gadgeel; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

CISH Inactivated TILs in the Treatment of NSCLC

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients